Global Prostate Cancer Nuclear Medicine Diagnostics Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prostate Cancer Nuclear Medicine Diagnostics Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Nuclear medicine, a type of imaging that uses radioactive materials, is a useful tool to detect and also treat prostate cancer. It is a form of diagnostic imaging that helps radiologists determine the stage of cancer.
Prostate Cancer Nuclear Medicine Diagnostics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Prostate Cancer Nuclear Medicine Diagnostics market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Prostate Cancer Nuclear Medicine Diagnostics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Prostate Cancer Nuclear Medicine Diagnostics key companies include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, Jubilant Pharma, NCM-USA, Progenics Pharma, Telix Pharma and ImaginAb, etc. Blue Earth Diagnostics, PETNET Solutions, Cardinal Health are top 3 players and held % share in total in 2022.
Prostate Cancer Nuclear Medicine Diagnostics can be divided into SPECT and PET, etc. SPECT is the mainstream product in the market, accounting for % share globally in 2022.
Prostate Cancer Nuclear Medicine Diagnostics is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Prostate Cancer Nuclear Medicine Diagnostics industry development. In 2022, global % share of Prostate Cancer Nuclear Medicine Diagnostics went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostate Cancer Nuclear Medicine Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Segment by Type
SPECT
PET
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Prostate Cancer Nuclear Medicine Diagnostics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Prostate Cancer Nuclear Medicine Diagnostics introduction, etc. Prostate Cancer Nuclear Medicine Diagnostics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Prostate Cancer Nuclear Medicine Diagnostics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Prostate Cancer Nuclear Medicine Diagnostics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Prostate Cancer Nuclear Medicine Diagnostics market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Prostate Cancer Nuclear Medicine Diagnostics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Prostate Cancer Nuclear Medicine Diagnostics key companies include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, Jubilant Pharma, NCM-USA, Progenics Pharma, Telix Pharma and ImaginAb, etc. Blue Earth Diagnostics, PETNET Solutions, Cardinal Health are top 3 players and held % share in total in 2022.
Prostate Cancer Nuclear Medicine Diagnostics can be divided into SPECT and PET, etc. SPECT is the mainstream product in the market, accounting for % share globally in 2022.
Prostate Cancer Nuclear Medicine Diagnostics is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Prostate Cancer Nuclear Medicine Diagnostics industry development. In 2022, global % share of Prostate Cancer Nuclear Medicine Diagnostics went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostate Cancer Nuclear Medicine Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Segment by Type
SPECT
PET
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Prostate Cancer Nuclear Medicine Diagnostics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Prostate Cancer Nuclear Medicine Diagnostics introduction, etc. Prostate Cancer Nuclear Medicine Diagnostics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Prostate Cancer Nuclear Medicine Diagnostics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices